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1  | INTRODUCTION
Invasive aspergillosis(IA) affects immunocompromised hosts, mainly 
patients with neutropenia, haematological malignancies or patients 
under allogeneic hematopoietic stem cell transplantation and is asso-
ciated with high mortality rates.1,2 During the past two decades, IA has 
been documented also in critically ill non- immunocompromised pa-
tients with certain risk factors (mainly chronic obstructive pulmonary 
disease (COPD), cirrhosis, prior surgical operations, severe sepsis) and 
reflecting an incidence between 2.7% and 5.8%.1-4 The antemortem 
definite diagnosis of IA in critically ill patients requires biopsy and his-
topathological evidence of Aspergillus spp. However, in this population, 
coagulation disorders are common, rendering any invasive procedure 
extremely risky.5 Therefore, the histopathological data concerning ICU 
patients with IA are limited, and derived mainly from autopsy studies.6
According to the available reports, Aspergillus spp can lead to 
perivascular and angio- invasive aspergillosis, characterised by an-
gioinvasion, thrombosis, vasculitis, and infarction caused by toxins 
produced by Aspergillus spp.7 Subsequent fungaemia and systemic 
embolisation can result in dissemination of almost every major organ 
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Summary
Invasive aspergillosis(IA) is a potentially lethal complication of Aspergillus infection af-
fecting mainly immunocompromised hosts; however, during the last two decades its 
incidence was increasingly observed in critically ill immunocompetent patients. The 
objective of this study is to describe the clinical characteristics of histologically proven 
endomyocardial and pericardial invasion, in the context of IA, in critically ill patients. 
Eight critically ill patients with histopathological confirmation of endomyocardial/peri-
cardial aspergillosis were evaluated. Risk factors, clinical and laboratory characteris-
tics, treatment, histopathological characteristics and mortality were recorded. Signs 
and symptoms of cardiac dysfunction were not observed in any of the patients. 
Therapy was administered to six of them shortly after the first positive culture. The 
observed histopathological lesions included haemorrhagic lesions, small vessels with 
central thrombosis and surrounding consolidated tissue with necrosis. Voriconazole, 
caspofungin, lipid amphotericin B and itraconazole were the used antifungals. The 
mortality rate was high (87.5%). Endomyocardial and pericardial aspergillosis are dev-
astating complications of invasive aspergillosis. Clinical suspicion is low making the 
diagnosis difficult, therefore histopathological examination of tissues are required. 
The mortality is high.
K E Y W O R D S
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system, including lung, central nervous system and heart.3,8 Except 
from haematogeneous spread, endomyocardium can be directly in-
vaded, through the dissemination of fungus to the left atrial wall and 
pulmonary veins, in the context of invasive pulmonary aspergillosis 
(IPA).9Additionally, direct pericardial invasion, following pulmonary as-
pergillosis, can lead to pericarditis.10 The objective of this study is to 
describe the risk profile, clinical presentation, therapy and outcome of 
a series of critically ill patients with IA and histopathological evidence 
of endomyocardial and/or pericardial disease.
2  | PATIENTS AND METHODS
We used data from the Aspergillus in the intensive care unit (AspICU) 
project, an international multicenter observational cohort study 
where	 563	 adult	 ICU	 patients	 were	 included	 from	 eight	 countries.	
Study methods have been described in detail elsewhere.2 The col-
lected data regarded demographics, acute organ failures, clinical signs 
compatible with invasive fungal disease, and underlying conditions 
including host factors for invasive fungal disease: neutropenia (less 
than 500 neutrophils/mm3 for 110 days), receipt of allogeneic stem 
cell	transplant,	prolonged	use	of	corticosteroids	(>	3	months)	or	high	
doses treatment (>20 mg/d), therapy with T- cell immunosuppressants 
and inherited severe immunodeficiency. Mycological examination 
encompassed culturing and galactomannan detection. Radiographic 
assessment included findings from chest X- ray and CT scan and CT 
imaging of sinuses, abdomen and central nervous system. Diagnosis 
of endomyocardial/pericardial aspergillosis required histopathological 
(autopsy or biopsy) evidence of Aspergillus involvement of endomyo-
cardium and/or pericardium.2 Descriptive variables are reported as n 
(%) or median (interquartile range). Local ethics committees or review 
boards provided approval for the study. Because of the observational 
nature of the study, informed consent was waived.
3  | RESULTS
In	the	AspICU	study,	563	(100%)	patients	were	recruited.	From	these	
patients,	 the	diagnosis	of	 IPA	was	confirmed	 in	79	 (14.03%)	by	bi-
opsy or autopsy. Among those cases, endomyocardial/pericardial as-
pergillosis was confirmed in eight (1.4%) patients (demographics are 
presented in Table 1). In all patients, lungs and endocardium were af-
fected by Aspergillus spp, pericardium in one patient while dissemina-
tion of the disease (non- coterminous organs involved) was present in 
four patients (1#, 2#,7# and 8#) (Table 2). Blood cultures for bacteria 
and fungi were negative in seven patients, whereas diagnosis was 
confirmed by biopsies in seven patients and autopsy in one patient. 
The histopathological findings included hemorrhagic lesions, small 
vessels with central thrombosis and surrounding consolidated tissue 
with necrosis. PAS and GMS stain for fungus demonstrated tissue in-
vasion by fungal hyphae and acute- angle branching. Macroscopically, 
the lesions appeared as ulcerated plaques. In one patient, the biopsy 
of endomyocardium was negative; however, pericardial involvement 
TABLE  1 Clinical and laboratory data of patients with 
endomyocardial/pericardial aspergillosis
Parameters
(N, %) and 
mean ± SE
AspICU study patients 563	(100%)
Confirmed by biopsy/autopsy IA 79	(14.3%)
Patients with endomyocardial/pericardial aspergillosis 8 (1.4%)
Sex (male/female) 3	(37.5%)/5	
(62.5%)
Age (years) 64±4
Admission diagnosis
Medical 6 (75%)
Surgical 2 (25%)
APACHE II score 26±3
SOFA score 13±1
Time between ICU admission and first positive culture 
(days)
18±8
Time between hospital admission and first positive 
culture (days)
31±6
Risk factors
Corticosteroid>20 mg/d 5 (62.5%)
Diabetes Mellitus 4 (50%)
ARDS 4 (50%)
Immunosuppressants 4 (50%)
Neutropenia 3	(37.5%)
Solid organ transplantation 3	(37.5%)
Chemotherapy 1 (12.5%)
Chronic heart failure 1 (12.5%)
COPD 1 (12.5%)
Haematological malignancies 1 (12.5%)
HIV 1 (12.5%)
Clinical Signs
Worsening respiratory failure 7 (87.5%)
Refractory	fever	(>3	days	after	initiation	of	
broad- spectrum antibiotics)
5 (62.5%)
Dyspnoea 3	(37.5%)
Pleural pain and rib 1 (12.5%)
Haemoptysis 1 (12.5%)
Radiological findings (non- specific)
CT scan of the lungs
Well described nodules 2 (25%)
Chest x- ray of the lungs
Non- specific infiltrates 6	(37.5%)
Time to treatment after first positive culture (days) 1.7
Used antifungal drugs
Caspofungin 3	(37.5%)
Voriconazole 2 (25%)
Lipid Amphotericin B 1 (12.5)
ICU length of stay (days) 30.3±0.6
Mortality 7 (87.5%)
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was detected confirming the diagnosis of pericardial aspergillosis. 
Due to low clinical suspicion and the insidious nature of the disease, 
echocardiogram studies were not performed in the majority of pa-
tients, although they could be early markers of endomyocardial and 
pericardial involvement. All eight patients required support with ino-
tropic	agents	and	the	mean	ICU	length	of	state	was	30+/−8	days.	As	
shown in Table 1 three patients were treated with caspofungin, two 
with voriconazole and one with lipid amphotericin B. In one patient 
treatment was withdrawn and the other patient died after the first 
positive culture. In patient 4# (Table 2) amphotericin B was changed 
to itraconazole which is an approved alternative for IA refractory 
to	 amphotericin	 with	 response	 rates	 ranging	 from	 38%	 to	 60%.	
Voriconazole use was not favoured due to concerns for additive liver 
and kidney toxicity as well as interactions with the immunosuppres-
sive agents (tacrolimus, sirolimus) that were administrated.11-13 The 
mortality was 87,5% (seven out of eight patients). The sole survivor 
was a renal transplant recipient who developed bilateral pneumonia 
and endocarditis by Aspergillus fumigatus. The patient had positive 
blood cultures and a large vegetation in tricuspid valve diagnosed by 
transesophageal echocardiography. No surgical repair was tried. He 
initially received caspofungin and after the culture results, he was 
changed to voriconazole. The whole length of therapy and the re-
spective follow- up period was 185 days.
4  | DISCUSSION
Aspergillus	spp	cause	20%-	30%	of	all	fungal	endocarditis	cases,	while	
a number of related risk factors have been recognised (cardiac abnor-
malities, prosthetic valves, malignancy, solid organ transplants, bone 
marrow transplants, steroid treatment, prolonged antibiotic exposure, 
haemaotological malignancy, chemotherapy and cytotoxic therapy).14 
Diagnosis requires a high index of suspicion; blood cultures are al-
most always negative and fungal vegetations are frequently large. 
Moreover, the incapacity to differentiate colonisation from infection 
further complicates the patient work- up. 4,15-17 Prognosis is poor, and 
medical therapy alone is almost always insufficient and it is unknown 
whether the presence of endocarditis worsens IPA prognosis.18 In the 
context of IPA, the impaired innate as well as adaptive immune re-
sponse that follows the Systemic Inflammatory Response Syndrome 
worsens even more the therapeutic outcome.6,19 Moreover, critically 
ill patients often present with thrombocytopenia and coagulation ab-
normalities which limit the capacity to perform biopsy and make diag-
nosis even more challenging.20
Despite the small number of cases presented, the study has been 
able to extract some significant findings. Concerning the pathogenesis 
of endomyocardial aspergillosis, our results seem to come into agree-
ment with the hypothesis of direct fungal invasion from lungs to left 
atrium through pulmonary veins.21-23 Indeed, only four of the eight pa-
tients manifested disseminated disease, while in the other four lungs 
and endocardium were impaired as well. From the invaded endocar-
dium fungi enter circulation leading to fungaemia and mycotic emboli-
sation indicating haematogenous dissemination as a result rather than 
cause of endomyocardial invasion. This finding diversifies endomyo-
cardial involvement from other common targets of invasive aspergil-
losis. As shown in a cohort relying on epidemiological data from many 
European ICUs, aspergillus was isolated in hepatic, peritoneal as well 
as cerebral samples that were suspected from lesions found on ab-
dominal and brain CTs respectively.24
Concerning histopathological examination, it is worth mentioning 
that although all patients presented the angio- invasive pattern of as-
pergillosis, only three of them were neutropenic. Stergiopoulou et al.25 
TABLE  2 Biopsy/Autopsy in eight patients with endomyocardial/pericardial aspergillosis
Patient Age Sex Admission Diagnosis Antifungal therapy APACHE II Death Involved organs
1 65 F Respiratory failure None 34 Yes Lung, abdomen, kidney, 
endocardium
2 61 M Spontaneous bacterial 
peritonitis
Caspofungin 27 Yes Lung, abdomen, liver, 
spleen, kidney, 
pancreas, endocardium
3 52 M Bilateral Pneumonia post 
renal transplantation
Caspofungin, voriconazole 17 No Lung, endocardium
4 62 F MRSA pneumonia, 
Klebsiella spp species
Ampho B lipid, itraconazole 37 Yes Lung, endocardium
5 74 F Stevens Johnson 
syndrome, Respiratory 
failure
Caspofungin 26 Yes Lung, endocardium
6 70 F Bilateral pneumonia Voriconazole 30 Yes Lung, endocardium
7 4 M Liver transplant Voriconazole, Ampho B 
conventional
8 Yes Lung, brain, pericardium
8 79 M Bilateral pneumonia- 
Septic shock
None 32 Yes Lung, abdomen, liver, 
kidney, endocardium, 
pericardium
F, Female; M, Male.
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reported that the angio- invasive pattern of disease is highly sugges-
tive of a defect in innate immunity. Therefore, there must be research 
focused on discovering the functional or tissue- specific impairments 
that occur in patients presenting with IPA in order to increase the sen-
sitivity of our clinical assessment.
Lastly, it is essential to realise that a negative endomyocardial bi-
opsy does not exclude the probability of cardiac involvement in pul-
monary aspergillosis. This occurs because biopsy cannot assess the 
pericardial involvement which is in fact rarely diagnosed antemortem 
and is associated with poor prognosis. Patients may suffer from car-
diac tamponade, arrhythmias or infarction. Pericardial involvement 
results either from mycotic emboli deriving from pulmonary circula-
tion in the context of haematogenous dissemination or directly from 
endocardium.10,26-28 Pericardial fluid might be detected and is usually 
purulent. In fact, two of our patients showed pericardial involvement, 
confirmed by positive yeast cultures during patient autopsy. Both 
patients died. The low sensitivity of biopsy concerning diagnosis of 
Aspergillus pericarditis denotes that diagnosis resides from the care-
ful assessment of clinical, radiological, echocardiographic and histo-
pathological data and raises the question whether echocardiography 
or other diagnostic tools such as cardiac magnetic resonance imaging 
should be included as standard of care in all patients with the suspicion 
of the disease.29,30Echocardiography in particular, might reveal veg-
etations of valves or implanted devices, valvular regurgitation, atrial 
thrombi or fungal masses.31,32
In conclusion, endomyocardial aspergillosis consists of a rare yet 
severe complication of IPA, is associated with very high mortality and 
carries many unknown modalities concerning its appropriate work- up 
and therapeutic management. More studies are required in order to 
gather the appropriate data to develop efficient diagnostic and thera-
peutic approaches in order to improve the disease outcome.
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